ALL06 A Phase II trial of an intensive pediatric protocol incorporating post-induction stratification based on minimal residual disease levels for the treatment of adolescents aged 15 years and above, and young adults aged up to 40 years, with newly diagnosed acute lymphoblastic leukaemia (ALL)

DOI number 10.58109/yg0a-p623
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Matthew Greenwood (Royal North Shore Hospital)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 86 patients aged 15-40 years with newly diagnosed Acute Lymphoblastic Leukaemia
  • Modified form of BRM-2000 protocol in the 15-40 age group
  • Complete remission, disease-free survival and overall survival
  • Toxicity
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)

Cancer diagnosis

ANZCTR Reference ACTRN12611000814976
Publication(s)
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au